MMP
Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases, generally consisting of a single peptide, a propeptide domain, a catalytic domain with a highly conserved zinc-binding site and a haemopexin-like domain, that catalyze the degradation of all components of the extracellular matrix. Multiple studies have shown that MMPs are overexpressed in malignant tumor and involved in the process of tumor growth, invasion and metastasis. Thus, synthetic and naturally occurring MMP inhibitions have been investigated as anti-cancer agents for the treatment of a variety of cancers, which are divided into three pharmacologic categories, including collagen peptidomimetics and nonpeptidomimetics, tetracycline derivatives and bisphosphonates.
- A2577 Batimastat (BB-94)7 CitationSummary: MMP inhibitor
- A4049 Marimastat1 CitationTarget: MMPSummary: MMPs inhibitor,board spectrum
- A4050 GM 60012 CitationTarget: MMPSummary: Broad spectrum MMP inhibitor
- A4051 NSC 4050201 CitationTarget: MMPSummary: MT1-MMP inhibitor
- A3334 CTS-1027Summary: MMPs inhibitor
- C5818 MMP-2 Inhibitor IISummary: irreversible inhibitor of MMP-2
- A1038 Amyloid β-Peptide (10-20) (human)Summary: Initiates neurodegeneration in Alzheimer disease
- B5981 DC_AC50Summary: Selective Atox1 and CCS inhibitor
- C3232 NNGHSummary: cell-permeable, broad-spectrum inhibitor of MMPs
- C4081 MMP Inhibitor IISummary: MMPs inhibitor